Q Bio, a predictive assessment platform provider, raised USD 27 million in strategic funding led by TELUS Global Ventures, with participation from existing investors Khosla Ventures, Andreessen Horowitz, Founders Fund, and Kaiser Foundation Hospitals. The funding will propel Q Bio's Mark I full-body scanner toward market launch.
The funding will accelerate manufacturing plans for the Mark I scanner as Q Bio continues its regulatory approval process in the US. The Mark I offers full-body scans with quantifiable data across 3,000 anatomical measurements in a 10-minute scan. AI then generates a digital twin of the patient, assessing current concerns and predicting potential diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.